Nitric-Oxide Inhibition Altered Some WIN Tolerance Outcomes but Spared Analgesic Tolerance in Mice
A mouse experiment found that inhibiting nitric oxide synthesis changed tolerance to WIN 55,212-2's temperature and catalepsy effects, but not its analgesic effect. It also found no comparable change in the tested acute responses.
Acute controls narrowed the explanation
The investigators used L-NAME, an inhibitor of nitric oxide synthase, before the synthetic cannabinoid agonist. In the reported acute comparison, L-NAME did not modify WIN-induced analgesia, hypothermia or catalepsy. L-NAME by itself was ineffective on those tested measures at the selected dose. Those controls helped distinguish a repeated-exposure finding from a simple amplification of the first drug response.
Tolerance developed on different schedules
With daily WIN administration, complete tolerance appeared after different numbers of days for analgesia, hypothermia and catalepsy. Repeated L-NAME inhibited tolerance development for hypothermia and catalepsy while leaving analgesic tolerance intact. A global statement that the inhibitor prevented cannabinoid tolerance would therefore be inaccurate.
The proposed mechanism remained outcome-specific
The pattern implicated nitric-oxide-related mechanisms in selected adaptations. It did not identify one universal molecular explanation for every cannabinoid response. WIN is an experimental synthetic agonist, and the measured animal endpoints are not direct tests of human intoxication or driving performance.
Interpreting the evidence
The useful conclusion is selective modulation of tolerance under a defined regimen. These findings do not establish L-NAME as a safe or effective treatment for human cannabis tolerance.
Related reading: kinase involvement and direct receptor regulation.
Research reference
Spina E; Trovati A; Parolaro D; et al. (1998). A role of nitric oxide in WIN 55,212-2 tolerance in mice. European journal of pharmacology. doi:10.1016/s0014-2999(97)01543-4. Evidence basis: study abstract.
